Tively TRITON-TIMI 38 ACS with scheduled PCI: NSTEMI or UA 74 , 26 STEMI 13,608 61 (IQR, 530) 26 ,72 h NSTE, ,12 h PPCI, ,14 d other STE 100 Sufferers ,75 yrs Medically managed: 67 NSTEMI; 33 UA 7243 62 36 ,ten d With no ST-elevation Overall Medically managed: 70 NSTEMI; 30 UA 9326 66 39 ,ten d With out ST-elevationAmerican Journal of Therapeutics (2016) 23(6) www.americantherapeutics.comeNo. patients Age (yrs; median) Female ( ) Symptom duration ST deviation 1 mm or elevated biomarker at entry ( ) Prior MI ( ) Diabetes ( ) Significant exclusion criteriaTreatment ATreatment B21 25 Fibrinolysis ,24 h, OAC, c.i. to CLO, drugs strongly affecting CYP-450 3A, risk of bradycardia ASA, 7500 mg (325 mg permitted) once day-to-day + TIC (180 mg LD + 90 mg twice every day 6 90 mg at PCI) ASA, 7500 mg when each day + CLO (300 mg LD + 75 mg six 300 mg for PCI .24 h) Permitted Up to 12 mo (62, eventdriven) 61 and 27 19 10 during study CVD, NF MI, NF stroke 9.8 vs. 11.7, P , 0.Clopidogrel before coronary angiography Length of follow-up (minimum aximum) In-hospital PCI and use of GPI ( ), respectively Use of .1 DES ( ) CABG ( ) PEEP definition PEEP within a vs. B ( )18 23 Higher bleeding threat, anemia, thrombocytopenia, intracranial illness, any thienopyridine ,five d ASA, 7562 mg once day-to-day + PRA (60 mg LD + ten mg after daily) as much as 1 h post-PCI but not before angiography ASA, 7562 mg when everyday + CLO (300 mg LD + 75 mg once day-to-day) as much as 1 h post-PCI but not just before angiography Not permitted unless PPCI Median, 14.five mo (65) 99 and 55 47 2.7 in the course of study CVD, NF MI, or NF stroke 9.9 vs. 12.1, P , 0.44 43 39 38 History of TIA or stroke, PCI, or CABG within earlier 30 d, renal failure requiring dialysis, concomitant OAC ASA, #100 mg after everyday + ASA, #100 mg after PRA (30 mg LD + 5 mg as soon as day-to-day + PRA (30 mg everyday)LD + 50 mg after each day)ASA, #100 mg when ASA, #100 mg as soon as each day + each day + CLO (30000 CLO (30000 mg LD + 75 mg mg LD + 75 mg once when day-to-day)everyday)Allowed Permitted Not stated Median, 17.1 mo (60)six ; GPI use not Not stated stated Not stated Not stated 2 Not stated CVD, NF MI, NF stroke 13.9 vs. 16.0, P five 0.21 18.7 vs. 20.3, P five 0.(Continued on subsequent web page)Husted and BoersmaTable 1. (Continued) Summary of characteristics and outcomes from 3 big trials of antiplatelet agents (PLATO, TRITON-TIMI-38, and TRILOGY-ACS).two TRILOGY-ACS PLATO* Relative (absolute) danger reduction ( ) Death in a vs. B ( ) CVD within a vs. B ( ) NF MI inside a vs. B ( ) Definite + probable ST in a vs. B ( ) NF stroke within a vs.2,3-Dibromopropene custom synthesis B ( ) Significant bleed definitionMajor bleed in a vs. B ( ) Non-CABG main bleed in a vs. B ( )CABG-related major bleed inside a vs. B ( ) Life-threatening bleed inside a vs. B ( ) Intracranial bleed within a vs. B ( ) Fatal bleed inside a vs. B ( ) NNT and (non-CABG) NNH for any vs. B 16 (1.9) 4.5 4.0 5.eight 2.2 vs. vs. vs. vs. 5.9, 5.1, 6.Price of 2089292-48-6 9, 2.PMID:27217159 9, P P P P , five 5 5 0.001 0.001 0.005 0.02 TRITON-TIMI 38 19 (2.2) 3.0 2.1 7.3 1.1 vs. vs. vs. vs. 3.2 2.four 9.5, P , 0.001 2.four, P , 0.001 Patients ,75 yrs 9 (two.1) 7.8 vs. eight.1, P five 0.63 six.six vs. six.eight, P 5 0.48 eight.three vs. ten.five, P 5 0.21 Not stated 1.5 vs. two.2, P five 0.08 TIMI non-CABGk two.1 vs. 1.5, P five 0.27 2.1 vs. 1.five, P 5 0.27 Not stated 0.9 vs. 0.eight, P 5 0.88 0.7 vs. 0.five, P 5 0.39 0.five vs. 0.2, P five 0.99 NA four (1.6) 11.6 vs. 12.two, P five 0.40 9.9 vs. 10.2, P 5 0.38 ten.7 vs. 12.3, P five 0.58 Not stated two.2 vs. 2.6, P five 0.52 TIMI non-CABGk two.five vs. 1.eight, P five 0.29 2.5 vs. 1.eight, P five 0.29 Not stated 1.1 vs. 1.1, P 5 0.85 0.eight vs. 0.7, P five 0.42 0.6 vs. 0.4, P five 0.68 NA Overallwww.americantherapeutics.com A.